MTOR and skin squamous cell carcinoma: Subsequently, in the phase 1 CONTRAC-1 trial, twelve KTR with advanced cSCC received the PD-1 inhibitor, cemiplimab, while maintained on a mammalian target of rapamycin inhibitor (mTORi) and prednisone mini-pulse with each treatment cycle [6].